**Table G-10. Results data for glycoprotein IIb/IIIa inhibitors: composite and individual outcomes**

| **Study** | **Study Details** | **Outcome(s)****Length of Followup** | **Results Reported by Authors** |
| --- | --- | --- | --- |
| Anonymous, 199871PURSUIT Study | RCTTotal N: 10,948Good quality | Primary composite at 96 hrs:Total mortalityNonfatal MI | Eptifibatide 2.0 mcg/kg/min | 359/4722 |
| Placebo | 431/4739 |
| Primary composite at 7 days:Total mortalityNonfatal MI | Eptifibatide 2.0 mcg/kg/min | 477/4722 |
| Placebo | 550/4739 |
| Primary composite at 30 days:Total mortalityNonfatal MI | Eptifibatide 2.0 mcg/kg/min | 671/4722 |
| Placebo | 744/4739 |
| Total mortality at 96 hrs | Eptifibatide 2.0 mcg/kg/min | 42/4722 |
| Placebo | 33/4739 |
| Total mortality at 7 days | Eptifibatide 2.0 mcg/kg/min | 71/4722 |
| Placebo | 95/4739 |
| Total mortality at 30 days | Eptifibatide 2.0 mcg/kg/min | 165/4722 |
| Placebo | 175/4739 |
| Nonfatal MI at 96 hrs | Eptifibatide 2.0 mcg/kg/min | 335/4722 |
| Placebo | 393/4739 |
| Nonfatal MI at 7 days | Eptifibatide 2.0 mcg/kg/min | 439/4722 |
| Placebo | 493/4739 |
| Nonfatal MI at 30 days | Eptifibatide 2.0 mcg/kg/min | 595/4722 |
| Placebo | 640/4739 |
| TIMI major bleeding pre-catheterization | Eptifibatide 2.0 mcg/kg/min | 496/4679 |
| Placebo | 427/4696 |
| GUSTO severe bleeding pre-catheterization | Eptifibatide 2.0 mcg/kg/min | 70/4679 |
| Placebo | 42/4696 |
| Minor bleeding pre-catheterization | Eptifibatide 2.0 mcg/kg/min | 604/4679 |
| Placebo | 348/4696 |
| Length of hospital stay | Eptifibatide 2.0 mcg/kg/min | 9.4 days  |
| Placebo | 10.4 days |
| Anonymous, 199872PRISM Study | RCTTotal N: 3232Good quality | Primary composite at 48 hrs:Total mortalityNonfatal MIRefractory ischemia | Tirofiban | RR (95% CI): 0.67 (0.48-0.92), reference group UFH |
| Primary composite at 7 days:Total mortalityNonfatal MIRefractory ischemia | Tirofiban | RR (95% CI): 0.90 (0.73-1.11), reference group UFH |
| Primary composite at 30 days:Total mortalityNonfatal MIRefractory ischemia | Tirofiban | RR (95% CI): 0.92 (0.78-1.09), reference group UFH |
| Secondary composite at 48 hrs:Total mortalityNonfatal MI | Tirofiban | RR (95% CI): 0.76 (0.42-1.39), reference group UFH |
| Secondary composite at 7 days:Total mortalityNonfatal MI | Tirofiban | RR (95% CI): 0.77 (0.54-1.11), reference group UFH |
| Secondary composite at 30 days:Total mortalityNonfatal MI | Tirofiban | RR (95% CI): 0.80 (0.61-1.05), reference group UFH |
| Refractory ischemia at 48 hrs | Tirofiban | RR (95% CI): 0.65 (0.46-0.91), reference group UFH |
| Refractory ischemia at 7 days | Tirofiban | RR (95% CI): 0.91 (0.73-1.14), reference group UFH |
| Refractory ischemia at 30 days | Tirofiban | RR (95% CI): 0.98 (0.79-1.21), reference group UFH |
| Nonfatal MI at 48 hrs | Tirofiban | RR (95% CI): 0.64 (0.33-1.25), reference group UFH |
| Nonfatal MI at 7 days | Tirofiban | RR (95% CI): 0.84 (0.56-1.26), reference group UFH |
| Nonfatal MI at 30 days | Tirofiban | RR (95% CI): 0.95 (0.68-1.34), reference group UFH |
| Total mortality at 48 hrs | Tirofiban | RR (95% CI): 1.48 (0.42-5.27), reference group UFH |
| Total mortality at 7 days | Tirofiban | RR (95% CI): 0.63 (0.34-1.18), reference group UFH |
| Total mortality at 30 days | Tirofiban | RR (95% CI): 0.62 (0.41-0.93), reference group UFH |
| Major bleeding at 48 hrs | Tirofiban | 6/1616 |
| UFH | 6/1616 |
| Minor bleeding at 48 hrs | Tirofiban | 32/1616 |
| UFH | 32/1616 |
| Anonymous, 199873PRISM-PLUS Study | RCTTotal N:1875Good quality | Primary composite at 48 hrs:Total mortalityNonfatal MIRehospitalizationRefractory ischemia | Tirofiban + UFH | RR (95% CI): 0.71 (0.48-1.04), reference group UFH |
| Primary composite at 7 days:Total mortalityNonfatal MIRehospitalizationRefractory ischemia | Tirofiban + UFH | RR (95% CI): 0.68 (0.53-0.88) , reference group UFH |
| Primary composite at 30 days:Total mortalityNonfatal MIRehospitalizationRefractory ischemia | Tirofiban + UFH | RR (95% CI): 0.78 (0.63-0.98) , reference group UFH |
| Primary composite at 6 mo:Total mortalityNonfatal MIRehospitalizationRefractory ischemia | Tirofiban + UFH | RR (95% CI): 0.81 (0.68-0.97) , reference group UFH |
| Secondary composite at 48 hrs:Total mortalityNonfatal MI | Tirofiban + UFH | RR (95% CI): 0.34 (0.14-0.79) , reference group UFH |
| Secondary composite at 7 days:Total mortalityNonfatal MI | Tirofiban + UFH | RR (95% CI): 0.57 (0.38-0.85) , reference group UFH |
| Secondary composite at 30 days:Total mortalityNonfatal MI | Tirofiban + UFH | RR (95% CI): 0.70 (0.51-0.96) , reference group UFH |
| Secondary composite at 6 mo:Total mortalityNonfatal MI | Tirofiban + UFH | RR (95% CI): 0.78 (0.59-1.01) , reference group UFH |
| Nonfatal MI at 48 hrs | Tirofiban + UFH | RR (95% CI): 0.32 (0.13-0.80) |
| Nonfatal MI at 7 days | Tirofiban + UFH | RR (95% CI): 0.53 (0.34-0.83) |
| Nonfatal MI at 30 days | Tirofiban + UFH | RR (95% CI): 0.70 (0.49-1.00) |
| Nonfatal MI at 6 mo | Tirofiban + UFH | RR (95% CI): 0.76 (0.59-1.01) |
| Total mortality at 48 hrs | Tirofiban + UFH | RR (95% CI): 0.51 (0.05-5.63) |
| Total mortality at 7 days | Tirofiban + UFH | RR (95% CI): 1.01 (0.49-2.06) |
| Total mortality at 30 days | Tirofiban + UFH | RR (95% CI): 0.79 (0.48-1.30) |
| Total mortality at 6 mo | Tirofiban + UFH | RR (95% CI): 0.97 (0.66-1.41) |
| Major bleeding in-hospital | Tirofiban + UFH | 31/773 |
| UFH | 24/797 |
| TIMI major bleeding at undefined time point | Tirofiban + UFH | 11/773 |
| UFH | 6/797 |
| Transfusion in-hospital | Tirofiban + UFH | 31/773 |
| UFH | 22/797 |
| Bhattacharya, 20101 | RCTTotal N: 301Good quality | Fatal MI at 7 days | Tirofiban | 1/136 |
| Placebo | 8/165 |
| Fatal MI at 14 days | Tirofiban | 1/122 |
| Placebo | 6/133 |
| Fatal MI at 30 days | Tirofiban | 2/105 |
| Placebo | 5/99 |
| Fatal MI at 3 mo | Tirofiban | 2/85 |
| Placebo | 2/64 |
| Nonfatal MI at 7 days | Tirofiban | 1/136 |
| Placebo | 8/165 |
| Nonfatal MI at 14 days | Tirofiban | 2/122 |
| Placebo | 9/133 |
| Nonfatal MI at 30 days | Tirofiban | 3/105 |
| Placebo | 5/99 |
| Nonfatal MI at 3 mo | Tirofiban | 2/85 |
| Placebo | 5/64 |
| Refractory ischemia at 7 days | Tirofiban | 10/136 |
| Placebo | 13/165 |
| Refractory ischemia at 14 days | Tirofiban | 10/122 |
| Placebo | 12/133 |
| Refractory ischemia at 30 days | Tirofiban | 14/105 |
| Placebo | 24/99 |
| Refractory ischemia at 3 mo | Tirofiban | 25/85 |
| Placebo | 36/64 |
| Death due to unknown causes at 7 days | Tirofiban | 2/136 |
| Placebo | 3/165 |
| Death due to unknown causes at 14 days | Tirofiban | 1/122 |
| Placebo | 1/133 |
| Death due to unknown causes at 30 days | Tirofiban | 0/105 |
| Placebo | 0/99 |
| Death due to unknown causes at 3 mo | Tirofiban | 1/85 |
| Placebo | 1/64 |
| Major bleeding at 7 days, 14 days, 30 days, and 3 mo | Tirofiban | 0/136 |
| Placebo | 0/165 |
| Momtahen, 200910  | RCTTotal N: 196Fair quality | Primary composite at 30 days:Total mortalityNonfatal MIRevascularization | Eptifibatide | 0/98 |
| Placebo | 16/98 |
| Nonfatal MI at 30 days | Eptifibatide | 0/98 |
| Placebo | 9/98 |
| Minor bleeding at 30 days | Eptifibatide | 7/98 |
| Placebo | 0/98 |
| Total mortality at 30 days | Eptifibatide | 0/98 |
| Placebo | 2/98 |
| Major bleeding at 30 days | Eptifibatide | 0/98 |
| Placebo | 0/98 |
| Revascularization at 30 days | Eptifibatide | 0/98 |
| Placebo | 4/98 |
| Okmen, 200374 | RCTTotal N: 83Fair quality | Secondary composite in-hospital:Total mortalityNonfatal MIRevascularizationRefractory angina | Tirofiban | 11/41 |
| No Tirofiban | 23/42 |
| Total mortality in-hospital | Tirofiban | 0/41 |
| No Tirofiban | 0/42 |
| Nonfatal MI in-hospital | Tirofiban | 1/41 |
| No Tirofiban | 8/42 |
| Revascularization in-hospital | Tirofiban | 1/41 |
| No Tirofiban | 0/42 |
| Major bleeding in-hospital | Tirofiban | 0/41 |
| No Tirofiban | 0/42 |
| Minor bleeding in-hospital | Tirofiban | 2/41 |
| No Tirofiban | 2/42 |
| Recurrent angina in-hospital | Tirofiban | 11/41 |
| No Tirofiban | 21/42 |
| Simoons, 200175GUSTO-IV Study | RCTTotal N: 7800Good quality | Primary composite at 48 hrs:Total mortalityNonfatal MI | Abciximab 24 hr | OR (95% CI): 1.3 (0.83-1.91), reference group placebo |
| Abciximab 48 hr | OR (95% CI): 1.5 (0.97-2.18) , reference group placebo |
| Primary composite at 7 days:Total mortalityNonfatal MI | Abciximab 24 hr | OR (95% CI): 0.9 (0.68-1.16) , reference group placebo |
| Abciximab 48 hr | OR (95% CI): 0.9 (0.69-1.18) , reference group placebo |
| Primary composite at 30 days:Total mortalityNonfatal MI | Abciximab 24 hr | OR (95% CI): 1.0 (0.83-1.24) , reference group placebo |
| Abciximab 48 hr | OR (95% CI): 1.1 (0.94-1.39) , reference group placebo |
| Total mortality at 48 hrs | Abciximab 24 hr | OR (95% CI): 2.3 (0.98-5.22) , reference group placebo |
| Abciximab 48 hr | OR (95% CI): 2.9 (1.28-6.44) , reference group placebo |
| Total mortality at 7 days | Abciximab 24 hr | OR (95% CI): 0.90 (0.55-1.30) , reference group placebo |
| Abciximab 48 hr | OR (95% CI): 1.1 (0.77-1.71) , reference group placebo |
| Total mortality at 30 days | Abciximab 24 hr | OR (95% CI): 0.90 (0.64-1.50) , reference group placebo |
| Abciximab 48 hr | OR (95% CI): 1.1 (0.83-1.43) , reference group placebo |
| Total mortality at 1 yr | Abciximab 24 hr | 212/2590 |
| Abciximab 48 hr | 235/2612 |
| Placebo | 203/2598 |
| Nonfatal MI at 48 hrs | Abciximab 24 hr | OR (95% CI): 1.0 (0.62-1.62) , reference group placebo |
| Abciximab 48 hr | OR (95% CI): 1.1 (0.68-1.73) , reference group placebo |
| Nonfatal MI at 7 days | Abciximab 24 hr | OR (95% CI): 0.90 (0.62-1.19) , reference group placebo |
| Abciximab 48 hr | OR (95% CI): 0.80 (0.60-1.15) , reference group placebo |
| Nonfatal MI at 30 days | Abciximab 24 hr | OR (95% CI): 1.1 (0.87-1.41) , reference group placebo |
| Abciximab 48 hr | OR (95% CI): 1.2 (0.91-1.46) , reference group placebo |
| Major bleeding in-hospital | Abciximab 24 hr | 16/2590 |
| Abciximab 48 hr | 26/2612 |
| Placebo | 8/2598 |
| Transfusion in-hospital | Abciximab 24 hr | 52/2590 |
| Abciximab 48 hr | 78/2612 |
| Placebo | 52/2598 |
| Song, 200776 | RCTTotal N: 204Good quality | Primary composite at 30 days: Total mortalityNonfatal MIRefractory ischemia | Tirofiban | 14/101 |
| Placebo | 29/99 |
| Total mortality at 30 days | Tirofiban | 1/101 |
| Placebo | 3/99 |
| Nonfatal MI at 30 days | Tirofiban | 3/101 |
| Placebo | 7/99 |
| Refractory ischemia at 30 days | Tirofiban | 12/101 |
| Placebo | 22/99 |
| Stone, 200642ACUITY Study | RCTTotal N: 13,819Good quality | Primary composite #1 at 30 days:Total mortalityNonfatal MIRevascularization | Bivalirudin | 360/4612 |
| Bivalirudin + GPI | 355/4604 |
| UFH/enoxaparin +GPI | 336/4603 |
| Primary composite #1 at 1 yr:Total mortalityNonfatal MIRevascularization | Bivalirudin | 585/3612 |
| Bivalirudin + GPI | 737/4604 |
| UFH/enoxaparin +GPI | 709/4603 |
| Primary composite #2 at 30 days:Total mortalityNonfatal MIRevascularizationMajor bleeding | Bivalirudin | 466/4612 |
| Bivalirudin + GPI | 543/4603 |
| UFH/enoxaparin +GPI | 539/4603 |
| Major bleeding at 30 days | Bivalirudin | 138/4612 |
| Bivalirudin + GPI | 244/4604 |
| UFH/enoxaparin +GPI | 262/4603 |
| Thrombocytopenia at 30 days | Bivalirudin | 457/4612 |
| Bivalirudin + GPI | 497/4604 |
| UFH/enoxaparin +GPI | 511/4603 |
| Minor bleeding at 30 days | Bivalirudin | 590/4612 |
| Bivalirudin + GPI | 999/4604 |
| UFH/enoxaparin +GPI | 994/4603 |
| Total mortality at 30 days | Bivalirudin | 74/4612 |
| Bivalirudin + GPI | 69/4604 |
| UFH/enoxaparin +GPI | 60/4603 |
| Total mortality at 1 yr | Bivalirudin | 175/4612 |
| Bivalirudin + GPI | 180/4604 |
| UFH/enoxaparin +GPI | 180/4603 |
| Nonfatal MI at 30 days | Bivalirudin | 249/4612 |
| Bivalirudin + GPI | 230/4604 |
| UFH/enoxaparin +GPI | 225/4603 |
| Nonfatal MI at 1 yr | Bivalirudin | 360/4612 |
| Bivalirudin + GPI | 327/4604 |
| UFH/enoxaparin +GPI | 318/4603 |
| Revascularization at 30 days | Bivalirudin | 111/4612 |
| Bivalirudin + GPI | 124/4604 |
| UFH/enoxaparin +GPI | 106/4603 |
| Revascularization at 1 yr | Bivalirudin | 401/4612 |
| Bivalirudin + GPI | 419/4604 |
| UFH/enoxaparin +GPI | 387/4603 |
| Stent thrombosis at 30 days | Bivalirudin | 11/1128 |
| Bivalirudin + GPI | 12/1165 |
| UFH/enoxaparin +GPI | 9/1112 |
| Length of hospital stay | Bivalirudin | Mean (SD): 3.4 +/- 3.3 days |
| Bivalirudin + GPI | Mean (SD): 3.5 +/- 3.5 days |
| UFH/enoxaparin +GPI | Mean (SD): 3.7 +/- 3.5 days |
| Stone, 200714ACUITY TIMING Study | RCTTotal N: 9,207Good quality | Primary composite at 30 days:Total mortalityNonfatal MIRevascularization | GPI upstream | 326/4605 |
| GPI deferred | 364/4602 |
| Secondary composite at 30 days:Total mortalityNonfatal MI | GPI upstream | 272/4605 |
| GPI deferred | 285/4602 |
| Secondary composite at 30 days:Total mortalityNonfatal MIRevascularizationMajor bleeding | GPI upstream | 539/4605 |
| GPI deferred | 538/4602 |
| Total mortality at 30 days | GPI upstream | 60/4605 |
| GPI deferred | 69/4602 |
| Nonfatal MI at 30 days | GPI upstream | 211/4605 |
| GPI deferred | 230/4602 |
| Revascularization at 30 days | GPI upstream | 97/4605 |
| GPI deferred | 129/4602 |
| Major bleeding at 30 days | GPI upstream | 281/4605 |
| GPI deferred | 225/4602 |
| Van den Brand, 199577 | RCTTotal N: 60Fair quality | Primary composite at 30 days:Total mortalityNonfatal MIRecurrent ischemia | Abciximab | 1/30 |
| Placebo | 12/30 |
| Total mortality at 30 days | Abciximab | 0/30 |
| Placebo | 1/30 |
| Nonfatal MI at 30 days | Abciximab | 1/30 |
| Placebo | 3/30 |
| Recurrent ischemia at 30 days | Abciximab | 0/30 |
| Placebo | 7/30 |

Abbreviations: CI=confidence interval; GPI=glycoprotein IIb/IIIa inhibitor; GUSTO=global utilization of streptokinase and t-PA for occluded arteries; hr=hour/hours; kg=kilogram/kilograms; mcg=microgram/micrograms; MI=myocardial infarction; min=minute/minutes; mo=month/months; N=number of patients; OR=odds ratio; RCT=randomized controlled trial; RR=relative risk; SD=standard deviation; TIMI=thrombolysis in myocardial infarction; UFH=unfractionated heparin